All articles
Federal and state policy
When 340B reimbursement falls below acquisition cost: Potential implications of CMS’s OPPS proposal
Part D plans continue to tighten coverage, increase coinsurance and prior authorization in 2027
Developing an HEOR evidence generation strategy to support product launch
Examining the association of social determinants of health with outcomes in patients with pulmonary arterial hypertension
Applying patient preferences in treatment for triple negative breast cancer to value assessment
Case Study
MFP effectuation: Preventing a duplicate 340B discount
Federal and state policy
Webinar: After the midterms: What do the results mean for drug pricing, Medicare, and public health?
How MFN pricing in the final GLOBE Model will affect beneficiary OOP costs
Women's health
Women’s Health Initiative
Coverage and payment
Medicare’s proposed IPCI and modifier 25 changes could reduce dermatology reimbursement